Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Ibrutinib vs FCR in Intermediate Risk CLL (ERADIC)
NCT04010968Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Sep 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax and ibrutinib in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Minimal Residual Disease in Bone Marrow < 0.01% at Month 27. Started Sep 2019; status: completed.
02
Drugs
venetoclaxibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04010968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04010968.